LeadershipThe company is led by highly experienced executives with strong track records.
Product EfficacyMonthly injectable GLP-1 data suggests equivalent efficacy to a competing weekly product, with potentially better tolerability.
Therapeutics PipelineThe company's platform and pipeline of novel obesity peptide-based therapeutics offer key advantages relative to competing assets.